Your browser doesn't support javascript.
loading
Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis.
Lambru, Giorgio; Stubberud, Anker; Rantell, Khadija; Lagrata, Susie; Tronvik, Erling; Matharu, Manjit Singh.
Afiliação
  • Lambru G; Headache and Facial Pain Group, UCL Queen Square Institute of Neurology, London, UK.
  • Stubberud A; Department of Neuromedicine and Movement Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Rantell K; Department of Neurology, St. Olavs Hospital, Trondheim, Norway.
  • Lagrata S; Education Unit, UCL Queen Square Institute of Neurology, London, UK.
  • Tronvik E; Headache and Facial Pain Group, UCL Queen Square Institute of Neurology, London, UK.
  • Matharu MS; Headache and Facial Pain Group, The National Hospital for Neurology and Neurosurgery, London, UK.
J Neurol Neurosurg Psychiatry ; 92(3): 233-241, 2021 03.
Article em En | MEDLINE | ID: mdl-33361408
ABSTRACT

INTRODUCTION:

The management of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) remains challenging in view of the paucity of data and evidence-based treatment recommendations are missing.

METHODS:

In this single-centre, non-randomised, prospective open-label study, we evaluated and compared the efficacy of oral and parenteral treatments for SUNCT and SUNA in a real-world setting. Additionally, single-arm meta-analyses of the available reports of SUNCT and SUNA treatments were conducted.

RESULTS:

The study cohort comprised 161 patients. Most patients responded to lamotrigine (56%), followed by oxcarbazepine (46%), duloxetine (30%), carbamazepine (26%), topiramate (25%), pregabalin and gabapentin (10%). Mexiletine and lacosamide were effective in a meaningful proportion of patients but poorly tolerated. Intravenous lidocaine given for 7-10 days led to improvement in 90% of patients, whereas only 27% of patients responded to a greater occipital nerve block. No statistically significant differences in responders were observed between SUNCT and SUNA. In the meta-analysis of the pooled data, topiramate was found to be significantly more effective in SUNCT than SUNA patients. However, a higher proportion of SUNA than SUNCT was considered refractory to medications at the time of the topiramate trial, possibly explaining this isolated difference.

CONCLUSIONS:

We propose a treatment algorithm for SUNCT and SUNA for clinical practice. The response to sodium channel blockers indicates a therapeutic overlap with trigeminal neuralgia, suggesting that sodium channels dysfunction may be a key pathophysiological hallmark in these disorders. Furthermore, the therapeutic similarities between SUNCT and SUNA further support the hypothesis that these conditions are variants of the same disorder.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome SUNCT / Analgésicos / Anestésicos Locais / Anticonvulsivantes Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome SUNCT / Analgésicos / Anestésicos Locais / Anticonvulsivantes Idioma: En Ano de publicação: 2021 Tipo de documento: Article